754
Views
9
CrossRef citations to date
0
Altmetric
Review

Pharmacophores and biological activities of severe acute respiratory syndrome viral protease inhibitors

&
Pages 533-546 | Published online: 02 May 2007
 

Abstract

Coronaviruses usually cause diseases with minor syndromes. However, an infectious disease caused by a novel human coronavirus induced severe acute respiratory syndrome (SARS). This disease first occurred in late 2002 and rapidly spread from its origin in southern China to > 25 countries during the 2003 epidemic. It affected ~ 8000 patients resulting in ~ 800 fatalities, a high mortality rate. To combat the disease, scientists have carried out cell-based assays to find the inhibitors on viral replication or focused on specific targets for developing their inhibitors as possible therapeutic agents. A promising target for SARS drug development is a chymotrypsin-like cysteine protease, a main protease responsible for the maturation of functional proteins in the life cycle of the SARS coronavirus. Several groups of inhibitors have been identified through high-throughput screening and rational drug design. The inhibitors reported in the literature and described in the patents are summarised in this review. These compounds may be useful to combat SARS if it reoccurs in the future and in developing new drugs for other coronaviruses with the main proteases.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.